A pilot study of priming with granulocyte macrophage colony-stimulating factor plus all-trans retinoic acid combined with remission induction chemotherapy in patients with acute myeloid leukemia

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 32, Issue 3, 2009, Pages 227-232

  Shin, Ho Jin ^a   Chung, Joo Seop ^a   Choi, Young Jin ^a   Cho, Goon Jae ^a  

^a Pusan National University Hospital   (South Korea)

Author keywords

Acute myeloid leukemia; Granulocyte macrophage colony stimulating factor; Tretinoin

Indexed keywords

ANTHRACYCLINE; ANTIHISTAMINIC AGENT; CYTARABINE; DEXAMETHASONE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IDARUBICIN; PARACETAMOL; RETINOIC ACID; STEROID;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALLOGENEIC STEM CELL TRANSPLANTATION; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOLOGOUS STEM CELL TRANSPLANTATION; BILIRUBIN BLOOD LEVEL; BLEEDING; BONE PAIN; BRAIN HEMORRHAGE; CANCER COMBINATION CHEMOTHERAPY; CELL DIFFERENTIATION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL EVALUATION; CONJUNCTIVAL HEMORRHAGE; CONTINUOUS INFUSION; CONTROLLED STUDY; DELIRIUM; DIARRHEA; DISEASE FREE SURVIVAL; DIZZINESS; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FEVER; GENERALIZED EDEMA; GRANULOCYTE; HEART ARRHYTHMIA; HUMAN; HYPERLEUKOCYTOSIS; HYPERTENSION; INDUCED HYPOTENSION; INFECTION; KIDNEY DISEASE; LEUKEMIA CELL; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOCYTOSIS; LUNG CONGESTION; MALE; MUCOSA INFLAMMATION; MYELOID LEUKEMIA; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PERICARDIAL EFFUSION; PERIPHERAL NEUROPATHY; PILOT STUDY; PRURITUS; PSYCHOSIS; RETINOIC ACID SYNDROME; RISK REDUCTION; SIDE EFFECT; SKIN DEFECT; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ANTINEOPLASTIC AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PILOT PROJECTS; PROGNOSIS; REMISSION INDUCTION; SURVIVAL RATE; TREATMENT OUTCOME; TRETINOIN; YOUNG ADULT;

EID: 67749144122     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3181844d2e     Document Type: Article

References (29)

1. Cheson BD, Cassileth PA, Head DR, et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol. 1990;8:813-819.
2. Freireich EJ, Gehan EA, Sulman D, et al. The effect of chemotherapy on acute leukemia in the human. J Chronic Dis. 1961;14:593-608.
3. Hu ZB, Minden MD, McCulloch EA. Post-transcriptional regulation of bcl-2 in acute myeloblastic leukemia: significance for response to chemotherapy. Leukemia. 1996;10:410-416.
4. Bhalla K, Birkhofer M, Arlin Z, et al. Effect of recombinant GM-CSF on the metabolism of cytosine arabinoside in normal and leukemic human bone marrow cells. Leukemia. 1988;2:810-813.
5. Cannistra SA, Groshek P, Griffin JD. Granulocyte-macrophage colony-stimulating factor enhances the cytotoxic effects of cytosine arabinoside in acute myeloblastic leukemia and in the myeloid blast crisis phase of chronic myeloid leukemia. Leukemia. 1989;3:328-334.
6. Miyauchi J, Kelleher CA, Wang C, et al. Growth factors influence the sensitivity of leukemic stem cells to cytosine arabinoside in culture. Blood. 1989;73:1272-1278.
7. Hiddemann W, Kiehl M, Zuhlsdorf M, et al. Granulocyte-macrophage colony-stimulating factor and interleukin-3 enhance the incorporation of cytosine arabinoside into the DNA of leukemic blasts and the cytotoxic effect on clonogenic cells from patients with acute myeloid leukemia. Semin Oncol. 1992;19:31-37.
8. Tanaka M. Recombinant GM-CSF modulates the metabolism of cytosine arabinoside in leukemic cells in bone marrow. Leuk Res. 1993;17:585-592.
9. Lista P, Porcu P, Avanzi GC, et al. Interleukin 3 enhances the cytotoxic activity of 1-beta-D-arabinofuranosylcytosine (ara-C) on acute myeloblastic leukaemia (AML) cells. Br J Haematol. 1988;70:121-123.
10. Bhalla K, Holladay C, Arlin Z, et al. Treatment with interleukin-3 plus granulocyte-macrophage colony-stimulating factors improves the selectivity of Ara-C in vitro against acute myeloid leukemia blasts. Blood. 1991;78: 2674-2679.
11. Inatomi Y, Toyama K, Clark SC, et al. Combinations of stem cell factor with other hematopoietic growth factors enhance growth and sensitivity to cytosine arabinoside of blast progenitors in acute myelogenous leukemia. Cancer Res. 1994;54:455-462.
12. Reuter C, Auf der Landwehr U, Schleyer E, et al. Modulation of intracellular metabolism of cytosine arabinoside in acute myeloid leukemia by granulo-cyte-macrophage colony-stimulating factor. Leukemia. 1994;8:217-225.
13. Hofmann WK, Heil G, Zander C, et al. Intensive chemotherapy with idaru-bicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia. Ann Hematol. 2004;83:498-503.
14. Pisani F, Del Poeta G, Aronica G, et al. In vitro down-regulation of bcl-2 expression by all-trans retinoic acid in AML blasts. Ann Hematol. 1997;75: 145-147.
15. Andreeff M, Jiang S, Zhang X, et al. Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid. Leukemia. 1999;13:1881-1892.
16. LehmannS, Paul C, TormaH. Retinoid receptor expression and its correlation to retinoid sensitivity in non-M3 acute myeloid leukemia blast cells. Clin Cancer Res. 2001;7:367-373.
17. Hu ZB, Minden MD, McCulloch EA. Phosphorylation of BCL-2 after exposure of human leukemic cells to retinoic acid. Blood. 1998;92:1768-1775.
18. Yang GS, Minden MD, McCulloch EA. Regulation by retinoic acid and hydrocortisone of the anthracycline sensitivity of blast cells of acute myeloblastic leukemia. Leukemia. 1994;8:2065-2075.
19. Hedley DW, McCulloch EA. Generation of reactive oxygen intermediates after treatment of blasts of acute myeloblastic leukemia with cytosine arabi-noside: role of bcl-2. Leukemia. 1996;10:1143-1149.
20. Hu ZB, Yang GS, Li M, et al. Mechanism of cytosine arabinoside toxicity to the blast cells of acute myeloblastic leukemia: involvement of free radicals. Leukemia. 1995;9:789-798.
21. Backway KL, McCulloch EA, Chow S, et al. Relationships between the mitochondrial permeability transition and oxidative stress during ara-C toxicity. Cancer Res. 1997;57:2446-2451.
22. Oka Y, Takeda K. Retinoic acid combined with GM-CSF induces morphological changes with segmented nuclei in human myeloblastic leukemia ML-1 cells. Anticancer Res. 1997;17:1951-1956.
23. Shimizu T, Takeda K. Induction of retinoic acid receptor-α by granulocyte-macrophage colony-stimulating factor in human myeloid leukemia cell lines. Cancer Res. 2000;60:4544-4549.
24. Bassan R, Chiodini B, Lerede T, et al. Prolonged administration of all-trans retinoic acid in combination with intensive chemotherapy and G-CSF for adult acute myelogenous leukemia: single-centre pilot study in different risk groups. Hematol J. 2002;3:193-200.
25. Oka Y, Takeda K. Retinoic acid combined with GM-CSF induces morphological changes with segmented nuclei in human myeloblastic leukemia ML-1 cells. Anticancer Res. 1997;17:1951-1955.
26. Shimizu T, Takeda K. Induction of retinoic acid receptor-alpha by granulocyte macrophage colony-stimulating factor in human myeloid leukemia cell lines. Cancer Res. 2000;60:4544-4549.
27. Preisler HD, Gao XZ, Chopra H, et al. Control of leukemia proliferation in vivo in patients: in vivo cytokine production. In: Hiddemann W, Buchner T, Wormann B, et al, eds. Acute Leukemias VII-Experimental Approaches and Novel Therapies. Springer: Berlin; 1998:307-316.
28. Muindi JR, Frankel SR, Huselton C, et al. Clinical pharmacology of oral all-trans retinoic acid in patients with acute promyelocytic leukemia. Cancer Res. 1992;52:2138-2142.
29. Ketley NJ, Allen PD, Kelsey SM, et al. Modulation of idarubicin-induced apoptosis in human acute myeloid leukemia blasts by all-trans retinoic acid, 1,25(OH)2 vitamin D3, and granulocyte-macrophage colony-stimulating factor. Blood. 1997;90:4578-4587.